Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trofinetide - ACADIA Pharmaceuticals/Neuren Pharmaceuticals

Next Previous
Drug Profile

Trofinetide - ACADIA Pharmaceuticals/Neuren Pharmaceuticals

Alternative Names: DAYBUE; DAYBUE STIX; G-2Me-PE; Glycyl-2-methyl-L-prolyl-L-glutamic acid; Glycyl-L-2-methylprolyl-L-glutamic acid; NNZ-2566

Latest Information Update: 11 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Neuren Pharmaceuticals
  • Developer ACADIA Pharmaceuticals; Neuren Pharmaceuticals; Walter Reed Army Institute of Research
  • Class Anti-inflammatories; Glutamates; Neuropeptides; Neuroprotectants; Oligopeptides; Pyrrolidines; Small molecules
  • Mechanism of Action Astrocyte inhibitors; Cytokine inhibitors; Glial cell inhibitors; Insulin-like growth factor I stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fragile X syndrome; Rett syndrome
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Rett syndrome
  • Phase II Brain injuries; Fragile X syndrome; Traumatic brain injuries
  • Discontinued Autistic disorder; Multiple sclerosis

Most Recent Events

  • 02 Mar 2026 Acadia plans to request a re-examination of the negative CHMP opinion on MAA of Trofinetide in Rett syndrome
  • 02 Mar 2026 CHMP issues negative opinion on MAA of Torfinetide in Rett syndrome
  • 25 Feb 2026 ACADIA Pharmaceuticals plans to launch trofinetide in US (PO, Powder) in early Q2 of 2026

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top